Investor Newsletter

Issue 12 2021

MicroPort®

MicroPort® Firehawk® Stent System Approved for Marketing in Australia

Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®) recently received registration approval from the Australian Therapeutic Goods Administration (TGA) for its Firehawk® Rapamycin Target Eluting Coronary Stent System (Firehawk®).

The approval of the Firehawk® in Australia, following the launch of the Firefighter® and Firefighter® NC balloon catheters not only demonstrates MicroPort®'s outstanding product portfolio in the field of interventional cardiology, but also further expands the company's global presence. MicroPort® continues to adhere to its brand philosophy of 'The Patient Always Comes First' and strives to provide premium total medical solutions for patients and doctors around the world.



MicroPort® Orthopedics Celebrates First Hip Replacement Surgery in Brazil Using the MicroPort® AnteriorPath® Technique

MicroPort® Orthopedics, a global leader in orthopedic devices and technologies, recently announced the successful completion of the first hip replacement surgery in Brazil using their MicroPort® AnteriorPath® hip surgical approach. AnteriorPath®, an anterior, portal-assisted approach for hip replacement, is designed to promote early rehabilitation of patients, helping them to achieve full function faster.

The surgery, led by Dr. Eduardo Gomes Machado, was completed in Jundiaí at the Hospital São Vicente de Paulo (HSV). While HSV had already adopted MicroPort® Orthopedic's SuperPath® hip technique in 2017, this surgery marks the first use of AnteriorPath® technique in Brazil, as well as Latin America. AnteriorPath® is an extension of the Direct Anterior approach, which uses a newly designed cannula to gain access to the acetabulum, offering direct visualization and in-line preparation of the acetabulum and femur. Dr. Eduardo Gomes Machado selected the AnteriorPath® due to its minimally invasive approach, which reduces the patient's recovery time.



MicroPort



MicroPort® CRM Receives CE Mark Approval for NAVIGO™ Left Ventricular Pacing Leads

MicroPort CRM, a pioneering company in the field of Cardiac Rhythm management, headquartered in France, recently received CE Mark approval under the new Medical Device Regulation (MDR – 2017/745) for its NAVIGO™ 4LV ARC and NAVIGO™ 4LV 2D leads, a new range of left ventricular pacing leads.

"NAVIGO™ leads demonstrated excellent performance during its clinical validation," said Benoît Clinchamps, President of MicroPort CRM. "In usual practice, the placement of the leads to pace the left ventricle can be very challenging given some coronary venous systems made of very small and tortuous veins. I am convinced that the easy handling and the very good electrical characteristics of NAVIGO™ leads will give physicians complete satisfaction. NAVIGO™ leads are the perfect complement of our CRT offer, after the launch in Europe, in July 2021, of GALI™, our latest implantable defibrillator featuring cardiac resynchronization (CRT-D)."

MicroPort

Fontus™ System of Endovastec™ Approved for Marketing by NMPA

Recently, the Fontus™ Branched Surgical Stent Graft System (Fontus™), developed by Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™), received approval for marketing by China's National Medical Products Administration (NMPA). This milestone marks Endovastec™'s 12th product to achieve NMPA approval since its establishment in 2012. In 2015, Fontus™ was selected for the Shanghai Industry-University-Research Special project in 2015, and was subsequently approved to enter the special approval process of NMPA for innovative medical devices in 2018.

Mr. Qing Zhu, President of Endovastec™, commented, "From the only surgical stent graft system in China, CRONUS™, to the first branched surgical stent graft system globally, Fontus™, the iterative products can reduce the difficulty of surgery, shorten the operation time, reduce postoperative complications of the nervous system and other organs, and provide a better solution for popularization of aortic dissection surgery, thus saving more patients with aortic dissection in the future."



Endovastec™ Receives Approval for Hercules™-LP Stent Graft System in India

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) recently received registration approval from the Indian Central Drugs Standard Control Organization (CDSCO) for its Hercules™ Low Profile Thoracic Stent Graft and Delivery System (Hercules™-LP). This milestone marks the first Endovastec™ product to be approved for marketing in India.



According to reports, India, the second most populous country in the world, suffers from a high prevalence of hypertension and diabetes, which are the main causes of aortic disease. The approval of Hercules™-LP in India will benefit more local patients with its excellent performance, providing both doctors and patients with a better solution for treating thoracic aortic disease and laying the foundation for the company to further develop overseas markets. The Hercules ™-LP received CE marking in 2020 and is currently available in several overseas countries in South America and Asia.

MicroPort

MicroPort NeuroTech™ Bridge® Vertebral Drug-Eluting Stent Presents in Frontiers in Neurology with PESS Results

MicroPort NeuroTech Limited (MicroPort NeuroTech™) has published the outcomes of the study 'Prospective Evaluation of Safety and Efficacy Vertebral Drug-eluting Stent System (PESS),' a pre-market clinical trial for the Bridge® Rapamycin Target Eluting Vertebral Stent System (Bridge®, previously known as Firehorus). The results were published in an article titled "Safety and Efficacy of Rapamycin-Eluting Vertebral Stents in Patients with Symptomatic Extracranial Vertebral Artery Stenosis" in Frontiers in Neurology, an authoritative journal in the field of neurology.

Prof. Zhongrong Miao noted, "The launch of Bridge® provides a reliable solution for the treatment of vertebral artery stenosis. The pre-market clinical data shows the superior performance of this stent. I believe it will become a bridge to ensure free-flowing blood in the vertebral artery, just as its name implies."


frontiers in Neurology

Endovascular and Interventional Neurology

ORIGINAL RESEARCH article

Safety and Efficacy of Rapamycin-Eluting Vertebral Stents in Patients With Symptomatic Extracranial Vertebral Artery Stenosis



VitaFlow Liberty™ by MicroPort®
CardioFlow Medtech Obtains Approval in Argentina

MicroPort CardioFlow Medtech Corporation (CardioFlow Medtech) recently announced that its transcatheter aortic valve implantation (TAVI) solution, the new-generation VitaFlow Liberty™ Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty™) has received marketing approval by the Argentine National Administration of Drugs, Foods, and Medical Devices (ANMAT).

The successful launch of VitaFlow Liberty™ in Argentina represents yet another milestone in the internationalization of CardioFlow Medtech. The rapid growth of the VitaFlow® product line in Latin America in the field of valve intervention provides a boost for CardioFlow Medtech to enter more overseas markets with high potential. In the future, CardioFlow Medtech will continue to accelerate the commercialization of innovative products with international competitiveness and introduce TAVI products to more countries and regions, bringing high-quality, universal total solutions for structural heart disease to more patients around the world.

MicroPort

MicroPort® MedBot® Completes the First Enrollment in Toumai® Single-Arm Surgical Robot Trial

Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort® MedBot®) has announced the completion of the First-in-Man (FIM) trial of a robotic-assisted single-port cholecystectomy using the Toumai® Single-Arm Laparoscopic Surgical Robot (Toumai® Single-Arm). The Toumai® Single-Arm developed by MicroPort® MedBot® in collaboration with a team led by Prof. Zhongtao Zhang from the Beijing Friendship Hospital, affiliated to Capital Medical University and Prof. Xun Li from the First Hospital of Lanzhou University. This is the first time that a single-arm laparoscopic surgery robot has been successfully used in gastrointestinal surgery in human trials, and marks a major milestone in a project led by Prof. Zhang under the auspices of the National Key R&D Program of the '13th Five-Year Plan' period.

Dr. Chao He, President of MicroPort® MedBot®, said, "At the moment, there is no single-arm laparoscopic surgical robot that is approved for marketing in China. In order to fill this gap, and with the support of the National Key Technologies R&D Program under the Ministry of Science and Technology, the team at MicroPort® MedBot® is working closely with universities, research institutes, and hospitals in a joint effort to complete the first Toumai® Single-Arm-assisted clinical trial. It also marks a further expansion of the scope of the Toumai® laparoscopic solutions. We will continue to enhance close cooperation with clinical specialists and deepen the exploration and innovation of cutting-edge technologies to provide patients and doctors with total surgical solutions powered by intelligent robotics that extend and reshape lives."

MicroPort® MedBot® Conducts Animal Testing Using Unmanned, Fully Automated Surgical Platform Madame Curie™ and Achieves Initial Success

Shanghai Microport MedBot (Group) Co. Ltd. (MicroPort® MedBot®) has announced that its Madam Curie™ Fully-Automated Unmanned Surgical Platform (Madam Curie™) was used for the first time in the animal testing phase of interventional cryoablation for treating prostatic hyperplasia. This is not only an initial success for Madam Curie™ in fully-automated percutaneous puncture surgeries, but also a key milestone in automated surgery research conducted by MicroPort® MedBot®.

Dr. Chao He, President of MicroPort® MedBot®, commented, "After years of exploration and development, the initial development of the unmanned, fully-automated Madam Curie™ surgical platform has been completed. This animal testing has laid an important foundation for understanding the feasibility of fully-automated surgical technology, and for its future application in clinical practice and markets. MicroPort® MedBot® will continue to contribute to the exploration and research of cutting-edge technologies represented by fully automated surgeries, lead the development of innovative technologies of surgical robots, and benefit more patients worldwide with intelligent robotic-enabled surgical solutions and services."

MicroPort® MedBot® Toumai® Mobile Showing & Training Center Launched

Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort® MedBot®) has announced the official launch of its independently-developed Toumai® Mobile Showing & Training Center (MSTC, Toumai® Mobile Platform). Executives from MicroPort® and MicroPort® MedBot® were joined by a number of high profile professionals at the launch event, which took place at the MicroPort® headquarters in Shanghai.

Mr. Dai expressed his expectations for the development of MicroPort® MedBot® during the launch event, commenting, “The National 14th Five-Year Plan, which encourages the development of intelligent manufacturing and the robotics industry, will spur the development of highly competitive robotic companies, leading to prosperity in the robotic industry in Shanghai. The MicroPort® Toumai® Mobile Platform is not just a training center but also an exhibition center that provides patients and hospital staff with a great demonstration of leading robotic technologies and surgical solutions.”

Mr. Yu Liu, Chief Commercial Officer of MicroPort® MedBot®, laid out the blueprint for the Toumai® platform, stating, "The launch of the Mobile Platform is a manifestation of MicroPort® MedBot®’s original aspiration of 'making every surgery simple'. Thanks to the convenience of the Toumai® Mobile Platform, we are able to travel across the country to every city we can access, in order to realize our dreams. The launch of Toumai® Mobile Platform today is just our first step. In the future, we will equip it with advanced robots for various segments developed by our group to bring intelligent total surgical solutions to doctors and patients alike.”

MicroPort

MicroPort®'s Four Sports Medicine Products Approved for Marketing

MicroPort Scientific Corporation (MicroPort®) has announced that four of its products under the Sports Medicine business unit have received medical device registration approvals from a number of drug administrations in China. These products — non-absorbable surgical suture series, arthroscopic cannulas, arthroscopic shoulder instruments and graft preparation system — are the first registration certificates in this listing since the founding of MicroPort® Sports Medicine and these approvals mark a significant milestone for the organization.

Dr. Liang Ge, General Manager of MicroPort® Sports Medicine, commented on this success, stating, "We will hold fast to the MicroPort® vision: to continue to develop innovative products and comply with high-quality global standards throughout the product lifecycle from design, manufacturing and sales, and to provide patients and physicians with comprehensive solutions for sports medicine."

In addition, Ms. Glendy Wang, Chairman of MicroPort® Sports Medicine, stated, "MicroPort® Sports Medicine will continue to strive for excellence in global leadership in sports medicine through innovative development, whilst maintaining an active role in the global industry. We will continue to provide physicians and patients with innovative, quality and inclusive solutions, and to help patients regain health and return to optimum movement."

Investor Newsletter

Issue 12 2021

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & VP of Securities Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com